Literature DB >> 28785191

Preoperative Plasma Levels of Total Testosterone Associated with High Grade Pathology-Detected Prostate Cancer: Preliminary Results of a Prospective Study in a Contemporary Cohort of Patients.

Antonio B Porcaro1, Nicolò De Luyk1, Paolo Corsi1, Marco Sebben1, Alessandro Tafuri1, Giovanni Cacciamani1, Davide De Marchi1, Irene Tamanini1, Davide Inverardi1, Matteo Brunelli2, Maria A Cerruto1, Gian L Salvagno3, Gian C Guidi3, Walter Artibani1.   

Abstract

OBJECTIVES: To investigate the associations, if any, between preoperative plasma levels of total testosterone (TT) and pathology Gleason score (pGS) in a contemporary cohort of prostate cancer (PCa) patients.
MATERIALS AND METHODS: Between November 2014 and June 2015, plasma levels of TT were measured in 142 patients who underwent radical prostatectomy. Exclusion criteria were as follows: 5α-reductase inhibitors, LH-releasing hormone analogues, or testosterone replacement treatment. The entire cohort, assessed by continuous and categorical variables, was classified into two groups according to the pGS that included low-intermediate (pGS 6-7) and high grade (pGS > 7) cases. TT was evaluated as a continuous variable.
RESULTS: The cohort included 128 cases. High grade PCa was detected in 28 (21.8%) patients. Median plasma levels of both TT and prostate specific antigen (PSA) were significantly higher in these cases. In the clinical multivariate model, independent and positive predictors of pGS > 7 were TT (p = 0.041; OR = 1.004), PSA (p = 0.006; OR = 1.191), and bGS > 6 (p = 0.004; OR = 5.0); that is, a single unit increase in TT plasma levels increases the odds of having high grade PCa by 4%.
CONCLUSION: In a contemporary cohort of patients, preoperative plasma levels of TT directly and independently associated with high grade PCa. High baseline plasma levels of TT might have clinical applications for managing PCa. New and well designed prospective studies dealing with this subject are required.

Entities:  

Keywords:  Hyptothalamus-pituitary-testis-prostate axis; Prostate cancer; Retropubic radical prostatectomy; Robot assisted radical prostatectomy; Testosterone

Year:  2017        PMID: 28785191      PMCID: PMC5527190          DOI: 10.1159/000447155

Source DB:  PubMed          Journal:  Curr Urol        ISSN: 1661-7649


  40 in total

1.  Low serum testosterone levels are predictive of prostate cancer.

Authors:  Luigi Mearini; Alessandro Zucchi; Elisabetta Nunzi; Tommaso Villirillo; Vittorio Bini; Massimo Porena
Journal:  World J Urol       Date:  2011-11-09       Impact factor: 4.226

2.  Circulating steroid hormones and the risk of prostate cancer.

Authors:  Gianluca Severi; Howard A Morris; Robert J MacInnis; Dallas R English; Wayne Tilley; John L Hopper; Peter Boyle; Graham G Giles
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-01       Impact factor: 4.254

3.  Cancer control with radical prostatectomy alone in 1,000 consecutive patients.

Authors:  Gerald W Hull; Farhang Rabbani; Farhat Abbas; Thomas M Wheeler; Michael W Kattan; Peter T Scardino
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

4.  Lower serum total testosterone is associated with lymph node metastases in a radical prostatectomy cohort study.

Authors:  Christian Kratzik; Irene Womastek; Christian Bieglmayer; Georg Schatzl; Jakob Lackner; Christa Freibauer; Gerhard Lunglmayr
Journal:  Anticancer Res       Date:  2011-10       Impact factor: 2.480

5.  Association between prostate cancer and serum testosterone levels.

Authors:  Ping L Zhang; Seymour Rosen; Ravindra Veeramachaneni; Jerry Kao; William C DeWolf; Glenn Bubley
Journal:  Prostate       Date:  2002-11-01       Impact factor: 4.104

6.  Along the pituitary-testis-prostate axis, serum total testosterone is a significant preoperative variable independently contributing to separating the prostate cancer population into prostatectomy Gleason score groups.

Authors:  Antonio B Porcaro; Aldo Petrozziello; Claudio Ghimenton; Filippo Migliorini; Teodoro Sava; Beatrice Caruso; Claudio Cocco; Mario Romano; Walter Artibani
Journal:  Anticancer Res       Date:  2012-11       Impact factor: 2.480

7.  Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging.

Authors:  Phillip M Pierorazio; Luigi Ferrucci; Anna Kettermann; Dan L Longo; E Jeffrey Metter; H Ballentine Carter
Journal:  BJU Int       Date:  2009-09-14       Impact factor: 5.588

8.  Influence of radical prostatectomy on serum hormone levels.

Authors:  L R Miller; A W Partin; D W Chan; D J Bruzek; A S Dobs; J I Epstein; P C Walsh
Journal:  J Urol       Date:  1998-08       Impact factor: 7.450

9.  Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer--a population-based case-control study.

Authors:  S O Andersson; H O Adami; R Bergström; L Wide
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

10.  Long-term outcome among men with conservatively treated localised prostate cancer.

Authors:  J Cuzick; G Fisher; M W Kattan; D Berney; T Oliver; C S Foster; H Møller; V Reuter; P Fearn; J Eastham; P Scardino
Journal:  Br J Cancer       Date:  2006-11-06       Impact factor: 7.640

View more
  2 in total

1.  Basal total testosterone serum levels predict biopsy and pathological ISUP grade group in a large cohort of Caucasian prostate cancer patients who underwent radical prostatectomy.

Authors:  Alessandro Tafuri; Marco Sebben; Riccardo Rizzetto; Nelia Amigoni; Aliasger Shakir; Tania Processali; Marco Pirozzi; Alessandra Gozzo; Katia Odorizzi; Mario De Michele; Sebastian Gallina; Alberto Bianchi; Paola Irene Ornaghi; Matteo Brunelli; Filippo Migliorini; Maria Angela Cerruto; Salvatore Siracusano; Walter Artibani; Alessandro Antonelli; Antonio B Porcaro
Journal:  Ther Adv Urol       Date:  2020-06-24

2.  Extent and predictors of grade upgrading and downgrading in an Australian cohort according to the new prostate cancer grade groupings.

Authors:  Kerri Beckmann; Michael O'Callaghan; Andrew Vincent; Penelope Cohen; Martin Borg; David Roder; Sue Evans; Jeremy Millar; Kim Moretti
Journal:  Asian J Urol       Date:  2019-03-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.